Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03630718
Other study ID # K180401J
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 27, 2019
Est. completion date May 22, 2023

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fatigue is a clinical symptom that has been described as the most disturbing by around 50% of patients with PBC. It has an important impact on patients' quality of life and is associated with an increased mortality risk. To treat fatigue in PBC, only medical treatments have been tested with limited efficacy or serious sides' effects. In other diseases, mostly cancer, psychological interventions showed efficacy on fatigue decrease. Most interventions consist in psychoeducation with: education about fatigue, development of self-care or coping techniques, activity management and learning to balance between activities and rest. Hypnosis, which consists in a body work for psycho-therapeutic use (e.g., through imagination), has also shown promising results. Moreover, psychological intervention efficacy seems to be influenced by patients' characteristics, such as personality. Therefore, the first aim of the present single-center randomized controlled phase 2 trial is to assess the efficacy of a psycho educational intervention and a hypnosis intervention on PBC patients' fatigue to demonstrate that both psychoeducational and hypnosis interventions decrease patient fatigue.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date May 22, 2023
Est. primary completion date May 17, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Women from 18 to 75 years old, - Diagnosis of primary biliary cholangitis (PBC) according to recognized criteria (EASL 2017), - Medically stable under treatment with UDCA initiated for at least 6 months, ie medically stable on the basis of liver biological parameters (no increase of more than 20% in bilirubin, ALP and transaminases) and absence of disabling pruritus (permanent and EVA> 6/10 or scratching lesions), - Presenting a significant level of fatigue (fatigue score on PBC-40>= 33), - Understanding the French language, - Availability and ability of the patient to access an internet network terminal to answer the online questionnaires of the study, - Signed consent form. Exclusion Criteria: - Presence of cirrhosis with a Child-Pugh B or C, - Presence of disabling pruritus (permanent, or EVA>= 7/10 in the last 3 weeks, or objectivable scratching skin lesions), - Patient on liver transplantation waiting list or total bilirubin> 50 µmol / L (3 mg / dL), or recent complication (<6 months) of cirrhosis (ascites, hepatic encephalopathy, rupture bleeding) of esophageal varices), - Untreated depressive disorder, - Any comorbidity not medically controlled (i.e. all dosage changes <3 months due to a control of the associated pathology deemed insufficient by the referring physician) or life-threatening in the medium term (within 2 years). - Psychiatric disorder modifying the relationship to the reality

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Psychoeducational Intervention
The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest. The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient.
Hypnosis intervention
The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being. Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue.

Locations

Country Name City State
France Service hépatologie Hôpital Saint-Antoine Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris University of Paris 5 - Rene Descartes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multidimensional fatigue inventory (MFI) (1) At Day 0
Primary Multidimensional fatigue inventory (MFI) (2) At week 5
Primary Multidimensional fatigue inventory (MFI) (3) At month 3
Primary Multidimensional fatigue inventory (MFI) (4) At month 6
Secondary Short Form Health Survey (SF36) (1) At Day 0
Secondary Short Form Health Survey (SF36) (2) At week 5
Secondary Short Form Health Survey (SF36) (3) At month 3
Secondary Short Form Health Survey (SF36) (4) At month 6
Secondary PBC-40 questionaire (1) At Day 0
Secondary PBC-40 questionaire (2) At week 5
Secondary PBC-40 questionaire (3) At month 3
Secondary PBC-40 questionaire (4) At month 6
Secondary Pittsburg Sleep Quality Inventory (PSQI) (1) At Day 0
Secondary Pittsburg Sleep Quality Inventory (PSQI) (2) At week 5
Secondary Pittsburg Sleep Quality Inventory (PSQI) (3) At month 3
Secondary Pittsburg Sleep Quality Inventory (PSQI) (4) At month 6
Secondary Epworth Sleeping Scale (ESS) (1) At Day 0
Secondary Epworth Sleeping Scale (ESS) (2) At week 5
Secondary Epworth Sleeping Scale (ESS) (3) At month 3
Secondary Epworth Sleeping Scale (ESS) (4) At month 6
Secondary Hospital Anxiety and Depression Scale (HADS) (1) At Day 0
Secondary Hospital Anxiety and Depression Scale (HADS) (2) At week 5
Secondary Hospital Anxiety and Depression Scale (HADS) (3) At month 3
Secondary Hospital Anxiety and Depression Scale (HADS) (4) At month 6
See also
  Status Clinical Trial Phase
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Terminated NCT00550862 - Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) Phase 2
Completed NCT00004748 - Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Phase 3
Completed NCT00004842 - Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Phase 1
Terminated NCT03633227 - Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Phase 4
Terminated NCT00125281 - SAMe to Treat Biliary Cirrhosis Symptoms Phase 2
Completed NCT04629456 - Physical Therapy for Liver Cirrhosis N/A
Completed NCT03468699 - Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia Phase 2
Completed NCT00006168 - Ursodiol-Methotrexate for Primary Biliary Cirrhosis Phase 3
Completed NCT00004784 - Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis Phase 3
Completed NCT00570765 - Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) Phase 2
Recruiting NCT00160940 - Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis N/A
Recruiting NCT03146910 - Swiss Primary Biliary Cholangitis Cohort Study
Terminated NCT03265249 - BRIDGE Device for Post-operative Pain Control N/A
Terminated NCT02308111 - Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Phase 4
Recruiting NCT02936596 - Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome N/A
Completed NCT00406237 - Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis Phase 1
Completed NCT04047160 - Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) Phase 1
Recruiting NCT00145964 - Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) N/A
Terminated NCT03476993 - Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis Phase 2